Skip to Content
Merck
  • Design, synthesis and biological evaluation of novel 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as aminopeptidase N/CD13 inhibitors.

Design, synthesis and biological evaluation of novel 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as aminopeptidase N/CD13 inhibitors.

Bioorganic & medicinal chemistry (2011-09-14)
Xiaopan Zhang, Jian Zhang, Lei Zhang, Jinghong Feng, Yingying Xu, Yumei Yuan, Hao Fang, Wenfang Xu
ABSTRACT

A series of novel 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives were designed, synthesized and assayed for their activities against aminopeptidase N (APN/CD13) and MMP-2. The results showed that most compounds exhibited higher inhibitory activities against APN than that of MMP-2. Within this series, compound 12h (IC(50)=6.28 ± 0.11 μM) showed similar inhibitory activities compared with Bestatin (IC(50)=5.55 ± 0.01 μM), and it could be used as novel lead compound for the future APN inhibitors development as anticancer agents.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
(S)-1,2,3,4-Tetrahydro-3-isoquinolinecarboxylic acid, 97%
Sigma-Aldrich
1,2,3,4-Tetrahydro-3-isoquinolinecarboxylic acid hydrochloride, 96%